Relationship between patient-reported outcomes and clinical outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the ADMIRAL study

被引：0
|
作者：
Cella, D. [1 ]
Ritchie, E. [2 ]
Fabbiano, F. [3 ]
Pigneux, A. [4 ]
Kanda, Y. [5 ]
Ivanescu, C. [6 ]
Pandya, B. J. [7 ]
Shah, M. V. [7 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Weill Cornell Med, New York, NY USA
[3] Azienda Osped Osped Riuniti Villa Sofia Cervello, Palermo, Italy
[4] CHU Bordeaux, Bordeaux, France
[5] Jichi Med Univ, Shimotsuke, Tochigi, Japan
[6] IQVIA, Amsterdam, Netherlands
[7] Astellas Pharma Inc, Northbrook, IL USA
来源：
SWISS MEDICAL WEEKLY | 2020年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P9
引用
收藏
页码：15S / 15S
页数：1
相关论文
共 50 条
  • [1] PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B.
    Shah, M., V
    VALUE IN HEALTH, 2019, 22 : S531 - S531
  • [2] The Relationship between Transplant Status and Patient-Reported Outcomes in Patients with FLT3-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
    Cella, David
    Ritchie, Ellen K.
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [3] The Relationship between Hospitalization and Patient-Reported Outcomes (PROs) in Patients with FLT3-Mutated (FLT3mut+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Results from the Phase 3 Admiral Study
    Ritchie, Ellen K.
    Cella, David
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V.
    BLOOD, 2019, 134
  • [4] Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML
    Ritchie, Ellen K.
    Cella, David
    Fabbiano, Francesco
    Pigneux, Arnaud
    Kanda, Yoshinobu
    Ivanescu, Cristina
    Pandya, Bhavik J.
    Shah, Manasee V. V.
    LEUKEMIA & LYMPHOMA, 2023, 64 (05) : 938 - 950
  • [5] PSYCHOMETRIC ANALYSIS OF PATIENT-REPORTED OUTCOME MEASURES IN FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Cella, D.
    Corredoira, L.
    Ivanescu, C.
    Pandya, B. J.
    Shah, M., V
    VALUE IN HEALTH, 2020, 23 : S83 - S83
  • [6] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W. -C.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S. -S.
    Lee, J. -H.
    Pardee, T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 295 - 295
  • [7] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL
    Perl, A. E.
    Martinelli, G.
    Cortes, J. E.
    Neubauer, A.
    Berman, E.
    Paolini, S.
    Montesinos, P.
    Baer, M. R.
    Larson, R. A.
    Ustun, C.
    Fabbiano, F.
    Di Stasi, A.
    Stuart, R.
    Olin, R.
    Kasner, M.
    Ciceri, F.
    Chou, W.
    Podoltsev, N.
    Recher, C.
    Yokoyama, H.
    Hosono, N.
    Yoon, S.
    Pardee, J. Lee T.
    Fathi, A. T.
    Liu, C.
    Liu, X.
    Bahceci, E.
    Levis, M. J.
    HAEMATOLOGICA, 2019, 104 : 2 - 2
  • [8] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [9] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
    Perl, Alexander E.
    Hosono, Naoko
    Montesinos, Pau
    Podoltsev, Nikolai
    Martinelli, Giovanni
    Panoskaltsis, Nicki
    Recher, Christian
    Smith, Catherine C.
    Levis, Mark J.
    Strickland, Stephen
    Rollig, Christoph
    Gross-Langenhoff, Marco
    Chou, Wen-Chien
    Lee, Je-Hwan
    Yokoyama, Hisayuki
    Hasabou, Nahla
    Lu, Qiaoyang
    Tiu, Ramon, V
    Altman, Jessica K.
    BLOOD CANCER JOURNAL, 2022, 12 (05)
  • [10] Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
    Alexander E. Perl
    Naoko Hosono
    Pau Montesinos
    Nikolai Podoltsev
    Giovanni Martinelli
    Nicki Panoskaltsis
    Christian Recher
    Catherine C. Smith
    Mark J. Levis
    Stephen Strickland
    Christoph Röllig
    Marco Groß-Langenhoff
    Wen-Chien Chou
    Je-Hwan Lee
    Hisayuki Yokoyama
    Nahla Hasabou
    Qiaoyang Lu
    Ramon V. Tiu
    Jessica K. Altman
    Blood Cancer Journal, 12
12345